Equities

TrivarX Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

TrivarX Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.031
  • Today's Change0.001 / 3.33%
  • Shares traded3.84m
  • 1 Year change+82.35%
  • Beta0.3975
Data delayed at least 20 minutes, as of Feb 12 2026 05:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.

  • Revenue in AUD (TTM)1.13m
  • Net income in AUD-943.23k
  • Incorporated1987
  • Employees4.00
  • Location
    TrivarX LtdLevel 4, 100 Albert RoadSOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 86189-1155
  • Fax+61 39077-9233
  • Websitehttps://medibio.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zelira Therapeutics Ltd660.00-3.63m7.20m8.00------10,905.73-0.3172-0.31720.00006-0.37490.00020.01020.003---118.74-50.35---56.97-1,236.3643.05-583,283.30-2,379.120.0244-6.50-----99.30-77.0790.08------
Immuron Ltd7.29m-5.22m9.80m7.00--0.8698--1.34-0.0226-0.02260.03160.03450.56751.504.401,041,000.00-40.62-27.84-49.64-30.6065.3970.18-71.58-182.344.19--0.00--48.6323.6724.81------
Tissue Repair Ltd3.02m-4.24m12.09m----0.8693--4.01-0.0701-0.07010.04990.23010.1777--60.84---24.96-24.25-26.50-25.27-----140.49-518.5422.40--0.00--236.85---2.43------
Calmer Co International Ltd8.03m-3.99m12.23m----6.33--1.52-0.0015-0.00150.00290.00061.603.2914.33---79.73-109.82-171.17-197.5042.4941.18-49.69-128.711.22-11.320.5482--88.4859.99-7.13--27.67--
Epsilon Healthcare Ltd6.13m-6.12m12.29m--------2.00-0.0164-0.01640.0167-0.00970.462--4.95---46.14-33.37-156.14-46.4652.2349.34-99.85-136.160.3775-3.921.67---15.813.16-403.56---32.83--
Firebrick Pharma Ltd293.42k-2.63m16.35m----9.38--55.73-0.0126-0.01260.00140.00690.13860.86960.4855---124.44-98.41-143.50-109.2835.72---897.84-5,384.554.75--0.00--1,920.80---124.04------
Oncosil Medical Ltd1.26m-15.10m18.60m2.00--3.23--14.74-1.37-1.370.11480.2170.182--2.18---217.79-97.54-382.54-117.83-78.62-54.05-1,196.80-1,258.41---146.890.022--116.34-15.15-26.74---6.31--
TrivarX Ltd1.13m-943.23k34.61m4.00--1.47--30.55-0.0018-0.00180.00230.02040.0923-------7.68-33.47-8.32-37.46-----83.27-373.85---27.050.0132--26.383.8934.25--6.29--
Vitura Health Ltd124.04m3.28m36.45m119.0010.190.75566.870.29390.00540.00540.20340.07281.6916.4310.46--4.1112.755.7217.6227.2130.972.436.061.059.500.2009--0.1341298.23-5.35--129.38--
Avecho Biotechnology Ltd1.38m-3.62m36.73m29.00--38.46--26.61-0.0011-0.00110.00040.00030.21154.461.91---55.49-61.23-72.92-73.2762.2755.45-262.41-382.044.53-8.030.0647--139.19-23.209.15------
Little Green Pharma Ltd38.49m5.86m37.44m--6.330.43533.860.97270.01940.01940.12680.28140.42620.819914.01--6.48--7.09--67.46--15.21--0.8728-4.710.0541--43.67--140.77------
Inoviq Ltd959.32k-6.93m47.16m85.00--2.24--49.16-0.0623-0.06230.00860.14970.04783.730.6725---34.52-43.01-37.36-45.8787.4589.08-722.62-1,543.445.72--0.022--21.1757.69-5.77------
Medical Developments International Ltd39.06m94.00k51.82m68.00547.620.940515.721.330.00080.00080.34690.48910.62211.065.31--0.1497-16.680.1738-18.9275.3572.700.2407-47.083.33--0.0349--17.8211.30100.23-24.33-34.91--
Data as of Feb 12 2026. Currency figures normalised to TrivarX Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

3.68%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 202533.29m2.89%
FIL Pensions Managementas of 30 Jun 20259.21m0.80%
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.